Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
07 Décembre 2009 - 2:30PM
PR Newswire (US)
CORALVILLE, Iowa, Dec. 7 /PRNewswire-FirstCall/ -- Vivakor, Inc.
(OTC Bulletin Board: VIVK) today announced the addition of new
Board of Directors members, Dr. Francis Chen and Fritz Lin, M.D.
Dr. Francis Chen brings over 20 years of healthcare experience to
his role as Board member of Vivakor, having held senior management
positions at Becton-Dickinson, Baxter Healthcare and Hygeia
Sciences/Tambrands among others. Dr. Chen earned his Ph.D. in
immunology from Harvard University, and holds an M.S. and a B.S. in
chemistry from Tufts University. Dr. Chen is Co-founder and
Chairman of Pacific Advantage International, a marketing and sales
support organization that assists U.S. and European information
technology companies in establishing sales and distribution
channels in the Asia-Pacific region. He is also Vice Chairman of
W.I. Harper, a venture capital firm operating in the US, China and
Taiwan, and serves on the board of Solar Power, Inc., Mail.com
Media Corporation, LogicEase Solutions, and Stealth Peptides. Fritz
Lin, M.D., is a Professor of Clinical Pathology and Interim
Chairman of the Department of Pathology and Laboratory Medicine at
the University of California, Irvine School of Medicine. He is also
the Director of Surgical Pathology & Cytopathology at the UCI
Medical Center and is a member of the Chao Family Comprehensive
Cancer Center. Dr. Lin is a highly respected clinician and is
recognized as a Best Doctor in America by Best Doctors, Inc., an
organization that bases its selection on survey results from other
physicians. Dr. Lin's research interests center on the applications
of principles of molecular biology, immunohistochemistry and
cytometry, and he is playing a key role in the development of a
human tumor tissue bank and various frozen tumor tissues for
molecular and biological studies. Vivakor CEO and Chief Scientific
Officer, Tannin Fuja, Ph.D. shared his thoughts on these new
members to the Vivakor team, "In the case of each of these
gentlemen, Vivakor is quite fortunate to be able to draw on their
experience and incredible wealth of knowledge in their respective
fields. Dr. Lin is, literally, an icon in his field and his
contribution to our scientific research cannot be underestimated.
Dr. Chen brings the marriage of science and business acumen to the
Board of Directors that will help guide its decisions well into the
future. We are a stronger company with their presence." About
Vivakor, Inc. Vivakor(TM) is a biomedical/biotechnology company
with transdisciplinary research that develops and acquires products
in the fields of molecular medicine, electro-optics, biological
handling and natural and formulary compounds that extend or improve
life. More information can be found about Vivakor at
http://www.vivakor.com/. FORWARD-LOOKING STATEMENTS This press
release may contain forward-looking statements which may be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," or "continue" and variations
or similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties discussed in Vivakor's filings with the
Securities and Exchange Commission, which factors are incorporated
herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. Vivakor
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this press release or to reflect actual outcomes. DATASOURCE:
Vivakor, Inc. CONTACT: Matt Nicosia of Vivakor, Inc.,
+1-319-625-2172, Web Site: http://www.vivakor.com/
Copyright